GERN
Geron Corporation NASDAQ Listed Jul 31, 1996$1.46
Mkt Cap $935.7M
52w Low $1.04
43.3% of range
52w High $2.01
50d MA $1.59
200d MA $1.40
P/E (TTM)
-12.2x
EV/EBITDA
-20.3x
P/B
4.7x
Debt/Equity
1.1x
ROE
-37.0%
P/FCF
-7.9x
RSI (14)
—
ATR (14)
—
Beta
0.67
50d MA
$1.59
200d MA
$1.40
Avg Volume
18.8M
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
919 East Hillsdale Boulevard · Foster City, CA 94404 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | BMO | -0.03 | -0.03 | +0.0% | 1.72 | +0.0% | -4.1% | -2.3% | -9.9% | -16.3% | -14.5% | — |
| Nov 5, 2025 | BMO | -0.04 | -0.03 | +18.3% | 1.09 | -1.8% | -0.9% | -1.8% | +6.4% | +14.7% | +13.8% | — |
| Aug 6, 2025 | BMO | -0.03 | -0.02 | +33.3% | 1.39 | +2.2% | -6.5% | -7.9% | -2.2% | -2.9% | +2.9% | — |
| May 7, 2025 | BMO | -0.04 | -0.03 | +25.0% | 1.31 | -0.8% | -3.8% | -9.9% | -2.3% | -8.4% | -9.2% | — |
| Feb 26, 2025 | BMO | -0.04 | -0.04 | +0.0% | 1.61 | -0.6% | +8.1% | +9.3% | +6.2% | +3.1% | +4.3% | — |
| Nov 7, 2024 | BMO | -0.09 | -0.04 | +55.6% | 4.29 | -1.9% | -0.9% | -4.0% | -7.5% | -9.8% | -13.5% | — |
| Aug 8, 2024 | BMO | -0.11 | -0.10 | +9.1% | 4.60 | +0.0% | +2.2% | +2.8% | -0.7% | -3.5% | -3.0% | — |
| May 2, 2024 | BMO | -0.10 | -0.09 | +10.0% | 3.95 | +1.3% | -0.5% | -5.6% | -2.0% | -3.5% | -1.8% | — |
| Feb 28, 2024 | BMO | -0.10 | -0.09 | +10.0% | 1.95 | +3.6% | +2.6% | +15.9% | +6.7% | +7.2% | +7.7% | — |
| Nov 2, 2023 | BMO | -0.10 | -0.08 | +20.0% | 1.78 | -1.1% | +11.2% | +3.9% | +7.3% | +3.9% | -1.7% | — |
| Aug 3, 2023 | BMO | -0.08 | -0.09 | -12.5% | 3.16 | -3.8% | -6.3% | -7.6% | -6.3% | -4.4% | -4.7% | — |
| May 11, 2023 | BMO | -0.09 | -0.07 | +22.2% | 2.89 | +2.1% | +7.3% | +5.2% | +3.5% | +4.5% | +3.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 5 | Needham | Maintains | Buy → Buy | — | $1.15 | $1.10 | -4.3% | -5.2% | -6.1% | -7.0% | +0.9% | +8.7% |
| May 8 | Scotiabank | Downgrade | Sector Outperform → Sector Perform | — | $1.31 | $1.30 | -0.8% | -3.8% | -9.9% | -2.3% | -8.4% | -9.2% |
| Mar 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $1.60 | $1.62 | +1.2% | +10.6% | +4.4% | +2.5% | +8.8% | +8.1% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $1.60 | $1.62 | +1.2% | +10.6% | +4.4% | +2.5% | +8.8% | +8.1% |
| Feb 27 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $1.61 | $1.60 | -0.6% | +8.1% | +9.3% | +6.2% | +3.1% | +4.3% |
| Feb 27 | Needham | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | +8.1% | +9.3% | +6.2% | +3.1% | +4.3% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $1.61 | $1.60 | -0.6% | +8.1% | +9.3% | +6.2% | +3.1% | +4.3% |
| Feb 27 | Stifel | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | +8.1% | +9.3% | +6.2% | +3.1% | +4.3% |
| Feb 26 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.37 | $1.73 | -27.0% | -32.1% | -26.6% | -25.7% | -27.8% | -30.0% |
| Feb 18 | B. Riley Securities | Maintains | Buy → Buy | — | $2.56 | $2.54 | -0.8% | +2.7% | -0.8% | +2.7% | +0.4% | -6.6% |
| Jan 13 | Needham | Maintains | Buy → Buy | — | $3.17 | $3.10 | -2.2% | -6.0% | -7.3% | -5.0% | -7.9% | -8.8% |
| Dec 13 | Needham | Maintains | Buy → Buy | — | $3.92 | $3.98 | +1.5% | -1.5% | -2.8% | +0.3% | -3.8% | -6.6% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.98 | $3.98 | +0.0% | +0.3% | +0.0% | -1.5% | -3.0% | -4.3% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.22 | $4.35 | +3.1% | +1.2% | +1.7% | +0.7% | -2.4% | -5.9% |
| Aug 9 | Needham | Maintains | Buy → Buy | — | $4.60 | $4.60 | +0.0% | +2.2% | +2.8% | -0.7% | -3.5% | -3.0% |
| Jul 26 | Needham | Maintains | Buy → Buy | — | $4.29 | $4.35 | +1.4% | +8.6% | +9.3% | +9.3% | +10.5% | +11.4% |
| Jun 10 | Stifel | Maintains | Buy → Buy | — | $4.59 | $4.58 | -0.2% | +9.8% | +10.9% | +10.9% | +6.3% | +6.1% |
| Jun 7 | Wedbush | Maintains | Outperform → Outperform | — | $3.89 | $4.46 | +14.7% | +18.0% | +29.6% | +30.8% | +30.8% | +25.4% |
| Jun 7 | Needham | Maintains | Buy → Buy | — | $3.89 | $4.46 | +14.7% | +18.0% | +29.6% | +30.8% | +30.8% | +25.4% |
| May 2 | Needham | Maintains | Buy → Buy | — | $4.08 | $4.14 | +1.5% | -3.2% | -3.7% | -8.6% | -5.1% | -6.6% |
| Apr 30 | Baird | Downgrade | Outperform → Neutral | — | $4.14 | $4.02 | -2.9% | -5.1% | -1.4% | -4.6% | -5.1% | -9.9% |
| Apr 11 | Needham | Maintains | Buy → Buy | — | $3.44 | $3.45 | +0.3% | +9.6% | +5.8% | +0.3% | +4.1% | +7.0% |
| Apr 10 | Wedbush | Maintains | Outperform → Outperform | — | $3.43 | $3.34 | -2.6% | +0.3% | +9.9% | +6.1% | +0.6% | +4.4% |
| Mar 15 | Goldman Sachs | Maintains | Buy → Buy | — | $1.75 | $3.00 | +71.4% | +92.0% | +81.7% | +86.3% | +96.6% | +90.3% |
| Mar 15 | Wedbush | Maintains | Outperform → Outperform | — | $1.75 | $3.00 | +71.4% | +92.0% | +81.7% | +86.3% | +96.6% | +90.3% |
| Mar 15 | Needham | Maintains | Buy → Buy | — | $1.75 | $3.00 | +71.4% | +92.0% | +81.7% | +86.3% | +96.6% | +90.3% |
| Mar 13 | Needham | Maintains | Buy → Buy | — | $1.88 | $1.83 | -2.7% | -6.9% | +78.7% | +69.1% | +73.4% | +83.0% |
| Mar 12 | Needham | Maintains | Buy → Buy | — | $2.14 | $1.93 | -9.8% | -12.1% | -18.2% | +57.0% | +48.6% | +52.3% |
| Mar 4 | Needham | Maintains | Buy → Buy | — | $2.26 | $2.26 | +0.0% | -8.0% | -7.5% | -7.1% | -7.1% | -0.4% |
| Feb 28 | Needham | Maintains | Buy → Buy | — | $2.07 | $2.10 | +1.4% | -5.8% | -3.4% | +9.2% | +0.5% | +1.0% |
| Sep 12 | Goldman Sachs | Upgrade | Neutral → Buy | — | $2.34 | $2.59 | +10.7% | -1.7% | -3.8% | -1.7% | -5.6% | -6.4% |
| Aug 29 | Wedbush | Maintains | Outperform → Outperform | — | $2.44 | $2.30 | -5.7% | -5.7% | -2.5% | -0.4% | +1.6% | +0.0% |
| Aug 4 | Needham | Maintains | Buy → Buy | — | $3.16 | $3.04 | -3.8% | -6.3% | -7.6% | -6.3% | -4.4% | -4.7% |
| Jun 15 | Needham | Maintains | Buy → Buy | — | $3.09 | $3.12 | +1.0% | -1.9% | -2.9% | +1.9% | +4.2% | +1.0% |
| Jun 5 | Needham | Maintains | Buy → Buy | — | $3.60 | $3.65 | +1.4% | +0.6% | +0.0% | -1.1% | +2.5% | +0.0% |
| May 12 | Wedbush | Maintains | Outperform → Outperform | — | $2.89 | $2.95 | +2.1% | +7.3% | +5.2% | +3.5% | +4.5% | +3.1% |
| Apr 21 | Needham | Maintains | Buy → Buy | — | $2.51 | $2.58 | +2.8% | +6.4% | +5.6% | -3.6% | -3.2% | -5.2% |
| Mar 28 | Goldman Sachs | Maintains | Neutral → Neutral | — | $2.34 | $2.31 | -1.3% | -7.3% | -4.7% | -8.5% | -7.3% | -7.3% |
| Mar 20 | B. Riley Securities | Maintains | Buy → Buy | — | $2.53 | $2.53 | +0.0% | -2.8% | -7.5% | -9.1% | -9.9% | -7.9% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $2.65 | $2.62 | -1.1% | -4.5% | -7.2% | -11.7% | -13.2% | -14.0% |
| Mar 17 | Wedbush | Maintains | Outperform → Outperform | — | $2.65 | $2.62 | -1.1% | -4.5% | -7.2% | -11.7% | -13.2% | -14.0% |
| Jan 9 | Needham | Maintains | Buy → Buy | — | $2.50 | $2.53 | +1.2% | +18.0% | +32.0% | +32.0% | +28.8% | +26.4% |
| Jan 4 | Wedbush | Maintains | Outperform → Outperform | — | $2.40 | $3.41 | +42.1% | +32.9% | +3.3% | +4.2% | +22.9% | +37.5% |
| Oct 28 | Wedbush | Maintains | Outperform → Outperform | — | $2.30 | $2.38 | +3.5% | +4.8% | -3.5% | -6.5% | -6.5% | -11.7% |
| Aug 22 | Needham | Maintains | Buy → Buy | — | $2.23 | $2.23 | +0.0% | -2.2% | +7.6% | +5.4% | +6.7% | +7.2% |
| Aug 12 | Needham | Maintains | Buy → Buy | — | $2.05 | $2.18 | +6.3% | +14.6% | +15.6% | +8.3% | +4.9% | +6.8% |
| May 10 | Needham | Maintains | Buy → Buy | — | $1.23 | $1.33 | +8.1% | +20.3% | +13.0% | +16.3% | +17.9% | +14.6% |
| Nov 2 | Baird | Maintains | Outperform → Outperform | — | $1.57 | $1.63 | +3.8% | +3.2% | +5.7% | +5.7% | +5.1% | +9.6% |
| Aug 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.76 | $1.95 | +10.8% | +4.0% | +7.4% | +9.7% | +16.5% | +10.2% |
| Aug 3 | Stifel | Maintains | Buy → Buy | — | $1.59 | $1.73 | +8.8% | +11.3% | +8.8% | +8.2% | +4.4% | +5.7% |
No insider trades available.
8-K
Unknown — 8-K Filing
Directors gain broad indemnification coverage for legal expenses and settlements, which may reduce accountability for questionable decisions and increase shareholder litigation risk and governance concerns.
Mar 26
8-K
Geron Corp -- 8-K Filing
Geron Corporation reported Q4 2025 and full-year 2025 financial results, highlighting business progress as it continues advancing its blood cancer treatment pipeline.
Feb 25
Data updated apr 25, 2026 11:13am
· Source: massive.com